长期管理策略 pegvaliase 在基尿的使用:从第三阶段的PRISM 开放式扩展研究中吸取的经验教训
Cary O Harding1, Kaleigh Bulloch Whitehall2, Joshua Lilienstein2
1Oregon Health & Science University, Portland, OR.
概括
对基尿症 (PKU) 的佩格瓦利酶治疗显示出可变的药理动力学. 一个分阶段的方法,考虑到免疫耐受性和血液中的氨酸水平,优化治疗以获得更好的结果.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 基尿症 (PKU) 是一种遗传性代谢障碍,导致氨酸 (Phe) 积累.
- 用佩格瓦里酶进行酶替代疗法旨在降低血液中的Phe水平.
- 个体的药理动力学变化需要个性化治疗策略.
研究的目的:
- 开发PKU患者佩格瓦酶的药理动力学/药理动力学模型.
- 了解基于药物清除的个体血液Phe模式.
- 为了确定最佳的治疗策略来管理Phe水平.
主要方法:
- 利用了PRISM第三阶段试验中的参与者级数据.
- 开发了一个药理动力学/药理动力学 (PK/PD) 模型.
- 分析了血液中的Phe水平,与佩格瓦里酶清除和免疫耐受性相关.
主要成果:
- 暴露于pegvaliase会导致免疫耐受性和降低药物清除.
- 血液Phe挥发性增加的时期 (120-200μmol/L Phe) 表明耐受性不完全.
- 在这个阶段减少剂量或放宽饮食可以导致显著的Phe增加.
结论:
- 对佩格瓦里酶的免疫耐受性在临床上呈现出特定的血液Phe模式.
- 建议采用分阶段的治疗方法:诱导耐受性,饮食自由化和逐步调整剂量.
- 这种模型有助于优化PKU管理的二酶疗法.
相关概念视频
Peritoneal Dialysis III: Nursing Management
168
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
168
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
261
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
261
Drug Administration and Therapy Phases: Overview
788
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
788
Cystic Fibrosis: Management
229
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
229
Chronic Kidney Disease III: Interprofessional Care
89
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
89
Chronic Pancreatitis II: Collaborative Care
133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
133


